Search bioRxiv⌕ Search

Biology subjects

Ughetto, M.

Publications and source records attributed to Ughetto, M..

4 recordsLinked to original sources

Representation Learning of Human Disease Mechanisms for a Foundation Model in Rare and Common Diseases

A fundamental challenge in translational medicine is the computational modeling of complex human diseases to accelerate therapeutic development. Representation learning provides a powerful framework to address this, yet creating models that capture deep biological mechanisms remains a critical need. To this end, we propose a novel strategy that partitions the disease landscape into rare and non-rare categories, enabling systematic knowledge repurposing both within and between these groups. Here, we introduce Dis2Vec (Disease to Vector), a representation learning framework designed to operationalize this concept. Dis2Vec generates biologically grounded disease embeddings by learning from human genetic and phenotypic data, forming the foundation for Disease-Disease Association Learning (DDAL) and unsupervised disease clustering. We evaluate Dis2Vec representations in two downstream applications. First, we assess DDAL performance on a transfer learning benchmark designed to predict therapeutic transferability, using real-world drug repurposing investment decisions made in clinical trials. Second, unsupervised clustering analyses reveal shared biological mechanisms across diseases. By modeling the disease landscape in this way, Dis2Vec enhances translational research efficiency across both rare and non-rare diseases, advancing the development of foundational models for therapeutic science. Furthermore, Dis2Vec establishes a biologically grounded disease-representation and benchmarking layer that paves the way for trustworthy agentic biomedical AI systems in rare-disease indication expansion.

systems biology↗

Community-aware explanations in knowledge graphs with XP-GNN

Machine learning applications for the drug discovery pipeline have exponentially increased in the last few years. An example of these applications is the biological Knowledge Graph. These graphs represent biological entities and the relations between them based on existing knowledge. Graph machine learning models such as Graph Neural Networks can be applied on top of knowledge graphs to support the development of novel therapeutics. Nevertheless, Graph Neural Networks present an improved performance at the expense of complexity, becoming difficult to explain their decisions. State-of-the-art explanation algorithms for Graph Neural Networks focus on determining the most relevant subgraphs involved in their decision-making while considering graph elements (nodes and edges) as independent entities and ignoring any communities these graphs could present. We explore in this work the idea that graph community structure in biological Knowledge Graphs could provide a better grasp of the decision-making of Graph Neural Networks. For that purpose, we introduce XP-GNN, a novel explanation technique for Graph Neural Networks in Knowledge Graphs. XP-GNN exploits the communities of nodes or edges in graphs to refine their explanations, inspired by cooperative game theory. We characterize XP-GNN in a basic example and in terms of scalability and stability. In two relevant use cases for the drug discovery pipeline, XP-GNN provides more relevant explanations than previous techniques, being evaluated quantitatively and by domain experts. At the same time, XP-GNN presents limitations on scalability and stability, which we will address. ACM Reference FormatAndres Martinez Mora, Dimitris Polychronopoulos, Michael Ughetto, and Sebastian Nilsson. 2024. Community-aware explanations in knowledge graphs with XP-GNN. In Proceedings of ACM Conference (Conference17). ACM, New York, NY, USA, 21 pages. https://doi.org/10.1145/nnnnnnn.nnnnnnn This work has been funded by AstraZeneca AB, Molndal, Sweden and AstraZeneca Cambridge. Unfortunately, due to proprietary reasons from AstraZeneca AB, the data used in this work cannot be shared.

bioinformatics↗

Biological Insights Knowledge Graph: an integrated knowledge graph to support drug development

The use of knowledge graphs as a data source for machine learning methods to solve complex problems in life sciences has rapidly become popular in recent years. Our Biological Insights Knowledge Graph (BIKG) combines relevant data for drug development from public as well as internal data sources to provide insights for a range of tasks: from identifying new targets to repurposing existing drugs. Besides the common requirements to organisational knowledge graphs such as being able to capture the domain precisely and give the users the ability to search and query the data, the focus on handling multiple use cases and supporting use case-specific machine learning models presents additional challenges: the data models must also be streamlined for the performance of downstream tasks; graph content must be easily customisable for different use cases; different projections of the graph content are required to support a wider range of different consumption modes. In this paper we describe our main design choices in implementation of the BIKG graph and discuss different aspects of its life cycle: from graph construction to exploitation.

systems biology↗

Knowledge Graph-based Recommendation Framework Identifies Novel Drivers of Resistance in EGFR mutant Non-small Cell Lung Cancer

Resistance to EGFR inhibitors (EGFRi) presents a major obstacle in treating non-small cell lung cancer (NSCLC). One of the most exciting new ways to find potential resistance markers involves running functional genetic screens, such as CRISPR, followed by manual triage of significantly enriched genes. This triage process to identify high value hits resulting from the CRISPR screen involves significant manual curation that requires specialized knowledge and can take even experts several months to comprehensively complete. To find key drivers of resistance faster we built a hybrid recommendation system on top of a heterogeneous biomedical knowledge graph integrating preclinical, clinical, and literature evidence. Genes were ranked based on trade-offs between diverse types of evidence linking them to potential mechanisms of EGFRi resistance. This unbiased approach identified 36 resistance markers from >3,000 genes, reducing hit identification time from months to minutes. In addition to reproducing known resistance markers, our method identified novel resistance mechanisms that we prospectively validated.

cancer biology↗